Nutriband Inc. (NASDAQ:NTRB) Short Interest Update

Nutriband Inc. (NASDAQ:NTRB - Get Free Report) saw a significant drop in short interest in March. As of March 15th, there was short interest totalling 222,300 shares, a drop of 20.9% from the February 28th total of 281,200 shares. Based on an average daily volume of 201,300 shares, the days-to-cover ratio is presently 1.1 days. Approximately 4.4% of the company's shares are short sold.

Institutional Investors Weigh In On Nutriband

A hedge fund recently bought a new stake in Nutriband stock. Haven Private LLC bought a new stake in Nutriband Inc. (NASDAQ:NTRB - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 11,561 shares of the company's stock, valued at approximately $54,000. Haven Private LLC owned about 0.10% of Nutriband as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 19.70% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Noble Financial initiated coverage on Nutriband in a report on Wednesday, January 22nd. They issued an "outperform" rating and a $13.00 price target for the company.

Nutriband Stock Up 2.0 %

Shares of NASDAQ NTRB traded up $0.11 during midday trading on Friday, reaching $5.61. The company's stock had a trading volume of 2,318 shares, compared to its average volume of 75,524. The stock has a 50 day simple moving average of $6.95 and a 200-day simple moving average of $5.87. The company has a current ratio of 4.96, a quick ratio of 4.83 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $62.30 million, a price-to-earnings ratio of -7.88 and a beta of 1.12. Nutriband has a fifty-two week low of $3.20 and a fifty-two week high of $11.78.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.